AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers

AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference

Five presentations at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD TM )

AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs

AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau, a protein in the brain that contributes to the disease. The interim data for ACI-35.030 come from the high-dose group in Phase 1b/2a trial of patients with early Alzheimer's.

AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer's Vaccine in High-dose Cohort

Results differentiate ACI-24 as potential best-in-class Abeta vaccine in development

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer's Disease

LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the SVB Leerink 11th Annual Global Healthcare Conference, taking place virtually February 14-18, 2022.

AC Immune to Present at the SVB Leerink 11th Annual Global Healthcare Conference

AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer's Vaccine Generates a Potent Immune Response

Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the rate of cognitive decline vs. placebo

AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer's Disease

AC Immune (ACIU) delivered earnings and revenue surprises of 17.24% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Reports Q3 Loss, Misses Revenue Estimates

The stock price of AC Immune SA (NASDAQ: ACIU) increased over 9% pre-market today. This is why it happened.

AC Immune (ACIU) Stock: Why The Price Increased Today

Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer's disease

AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

LAUSANNE, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it is extending its research partnership with leading scientists at the Center for Neurodegenerative Disease Research at the Perelman School of Medicine at the University of Pennsylvania (Penn). The partnership is focused on studying the pathological mechanism of transactive response DNA binding protein 43 kDa (TDP-43) misfolding, aggregation and cell-to-cell transmission.

AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a Major Driver of Neurodegenerative Diseases

LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases,  today announces that new data on its investigational Alzheimer's disease (AD) candidates semorinemab, ACI-35.030 and ACI-24 will be featured in the scientific program of the Clinical Trials on Alzheimer's Disease (C-TAD) Conference, taking place virtually and in person in Boston, on November 9-12, 2021.

New Data on AC Immune's Abeta and pTau Clinical Programs in Alzheimer's Disease To Be Presented at CTAD 2021

Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization

AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof.

LAUSANNE, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced its Co-Founder and CEO Andrea Pfeifer has been awarded by the Swiss Economic Forum (SEF) with the SEF.WomenAward, in the category CEO of the Year, during a ceremony at the SEF meeting in Interlaken on September 2, 2021.

AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year

LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in the following upcoming virtual investor conferences:

AC Immune to Participate in Upcoming Virtual Investor Conferences in September

AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%

AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study

Earlier today, AC Immune SA (NASDAQ:ACIU) announced semorinemab met one of its co-primary endpoints in a mid-stage Alzheimer's disease trial. SVB Leerink notes that semorinemab data is "good news.

What Leerink, Wainwright Have To Say For This Alzheimer's Focused Firm

AC Immune (ACIU) stock is rising higher on Tuesday after revealing positive results from a recent Alzheimer's disease study. The post ACIU Stock: The Big Alzheimer's News That Has AC Immune Skyrocketing Today appeared first on InvestorPlace.

ACIU Stock: The Big Alzheimer's News That Has AC Immune Skyrocketing Today

MIxed results for the company's Alzheimer's disease candidate are good enough for the market today.

Here's Why AC Immune Stock Is Surging Today

The shares of Switzerland-based biopharmaceutical company AC Immune SA (NASDAQ:ACIU) are soaring this morning, up 72.4% to trade at $12.04 at last check.

Biopharmaceutical Stock Blasts Higher on Alzheimer's Treatment Update

The stock price of AC Immune SA (NASDAQ: ACIU) increased by over 65% pre-market. This is why it happened.

ACIU Stock: Over 65% Increase Pre-Market Explanation

AC Immune SA (NASDAQ: ACIU) and its collaborating partner Genentech, part of Roche Holdings AG (OTC: RHHBY), have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD). Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale).

See Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate

Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11

News for AC Immune Stock (ACIU)